Adam P. Silverman
18Patents
4h-index
41Co-inventors
56Inventor score
Filing activity: Jan 18, 2010 → Apr 23, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10870837B2 | Fusion proteins comprising enzyme replacement therapy enzymes | Chemistry; Metallurgy | 9 | Active |
| US11124567B2 | Anti-TREM2 antibodies and methods of use thereof | Chemistry; Metallurgy | 7 | Active |
| US10143187B2 | Transferrin receptor transgenic models | Physics | 6 | Active |
| US8778888B2 | Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use | Human Necessities | 4 | Active |
| US11970722B2 | Engineered acid alpha-glucosidase variants | Emerging Cross-Sectional Technologies | 3 | Active |
| US8741839B2 | Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin | Human Necessities | 2 | Active |
| US11912778B2 | Methods of engineering transferrin receptor binding polypeptides | Chemistry; Metallurgy | 2 | Active |
| US11795232B2 | Engineered transferrin receptor binding polypeptides | Chemistry; Metallurgy | 2 | Active |
| US11866742B2 | Fusion proteins comprising enzyme replacement therapy enzymes | Chemistry; Metallurgy | 2 | Active |
| US9234021B2 | Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha V beta 3 integrin | Human Necessities | 1 | Active |
| US11124562B2 | Anti-ApoE antibodies | Chemistry; Metallurgy | 1 | Active |
| US11370832B2 | Anti-Tau antibodies and methods of use thereof | Chemistry; Metallurgy | 1 | Active |
| US12162948B2 | Methods of engineering transferrin receptor binding polypeptides | Chemistry; Metallurgy | 1 | Active |
| US9441026B2 | Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha V beta 3 integrin | Human Necessities | 0 | Active |
| US11926660B2 | Anti-ApoE antibodies | Chemistry; Metallurgy | 0 | Active |
| US11773185B2 | Anti-BACE1 antibodies and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US9505822B2 | Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin | Human Necessities | 0 | Active |
| US11612150B2 | Transferrin receptor transgenic models | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.